Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

(131)I and thyroid-associated ophthalmopathy.

A K Rasmussen1, B Nygaard, U Feldt-Rasmussen

  • 1Medical Department of Endocrinology, Rigshospitalet, University of Copenhagen, Denmark. aakr@rh.dk

European Journal of Endocrinology
|July 29, 2000
PubMed
Summary

Radioiodine therapy for hyperthyroidism may worsen thyroid-associated ophthalmopathy (TAO). Risk factors like smoking and thyroid function influence TAO, necessitating careful treatment selection and potential glucocorticoid use.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Risks of suboptimal and excessive thyroid hormone replacement across ages.

Journal of endocrinological investigation·2023
Same author

Long-term methimazole therapy in Graves' hyperthyroidism and adverse reactions: a Danish multicenter study.

European thyroid journal·2022
Same author

Standardising clinical outcomes measures for adult clinical trials in Fabry disease: A global Delphi consensus.

Molecular genetics and metabolism·2021
Same author

Association of Thyroid Function Test Abnormalities and Thyroid Autoimmunity With Preterm Birth: A Systematic Review and Meta-analysis.

JAMA·2019
Same author

THE ROMANIAN VERSION OF THE THYROID-RELATED PATIENT-REPORTED OUTCOMES THYPRO AND THYPRO-39. TRANSLATION AND ASSESSMENT OF RELIABILITY AND CROSS-CULTURAL VALIDITY.

Acta endocrinologica (Bucharest, Romania : 2005)·2019
Same author

Predictors of Initial and Sustained Remission in Patients Treated with Antithyroid Drugs for Graves' Hyperthyroidism: The RISG Study.

Journal of thyroid research·2019

Area of Science:

  • Endocrinology
  • Ophthalmology
  • Autoimmune diseases

Background:

  • Graves' disease is an autoimmune disorder often treated with radioiodine therapy.
  • Thyroid-associated ophthalmopathy (TAO) is an autoimmune condition linked to Graves' disease.
  • Radioiodine ((131)I) therapy is suspected of exacerbating or triggering TAO.

Purpose of the Study:

  • To review the literature on the effects of hyperthyroid treatments on TAO.
  • To identify risk factors influencing the progression of TAO.
  • To inform treatment decisions for hyperthyroidism in patients with or at risk of TAO.

Main Methods:

  • Systematic literature review.
  • Analysis of risk factors for TAO progression, including thyroid function, smoking, and (131)I therapy.

Related Experiment Videos

  • Evaluation of treatment modalities for Graves' hyperthyroidism.

    • Main Results:

    • Radioiodine ((131)I) therapy is a potential risk factor for worsening thyroid-associated ophthalmopathy (TAO).
    • Thyroid function status and cigarette smoking are significant risk factors influencing TAO.
    • The choice of hyperthyroid treatment modality impacts TAO outcomes.

    Conclusions:

    • Patients at higher risk for TAO worsening should be identified.
    • Treatment modality for hyperthyroidism should consider TAO risk.
    • Prophylactic systemic glucocorticoid treatment may be indicated for at-risk patients.